These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 25541061)

  • 1. Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance.
    Kareva I; Waxman DJ; Lakka Klement G
    Cancer Lett; 2015 Mar; 358(2):100-106. PubMed ID: 25541061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metronomic chemotherapy: A potent macerator of cancer by inducing angiogenesis suppression and antitumor immune activation.
    Biziota E; Mavroeidis L; Hatzimichael E; Pappas P
    Cancer Lett; 2017 Aug; 400():243-251. PubMed ID: 28017892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to metronomic chemotherapy and ways to overcome it.
    Riesco-Martinez M; Parra K; Saluja R; Francia G; Emmenegger U
    Cancer Lett; 2017 Aug; 400():311-318. PubMed ID: 28259819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ATP-binding cassette transporters in tumor endothelial cells and resistance to metronomic chemotherapy.
    Hida K; Kikuchi H; Maishi N; Hida Y
    Cancer Lett; 2017 Aug; 400():305-310. PubMed ID: 28216371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor endothelial cells as a potential target of metronomic chemotherapy.
    Kim JY; Kim YM
    Arch Pharm Res; 2019 Jan; 42(1):1-13. PubMed ID: 30604201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of vascular normalization in benefit from metronomic chemotherapy.
    Mpekris F; Baish JW; Stylianopoulos T; Jain RK
    Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1994-1999. PubMed ID: 28174262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.
    Cruz-Muñoz W; Di Desidero T; Man S; Xu P; Jaramillo ML; Hashimoto K; Collins C; Banville M; O'Connor-McCourt MD; Kerbel RS
    Angiogenesis; 2014 Jul; 17(3):661-73. PubMed ID: 24569856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Combination of Immune Checkpoint Inhibition with Metronomic Chemotherapy as a Way of Targeting Therapy-Resistant Cancer Cells.
    Kareva I
    Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29027915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metronomic chemotherapy and nanocarrier platforms.
    Abu Lila AS; Ishida T
    Cancer Lett; 2017 Aug; 400():232-242. PubMed ID: 27838415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
    Kerbel RS; Shaked Y
    Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells.
    Vives M; Ginestà MM; Gracova K; Graupera M; Casanovas O; Capellà G; Serrano T; Laquente B; Viñals F
    Int J Cancer; 2013 Nov; 133(10):2464-72. PubMed ID: 23649709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metronomic chemotherapy and immunotherapy in cancer treatment.
    Chen YL; Chang MC; Cheng WF
    Cancer Lett; 2017 Aug; 400():282-292. PubMed ID: 28189534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.
    Kamat AA; Kim TJ; Landen CN; Lu C; Han LY; Lin YG; Merritt WM; Thaker PH; Gershenson DM; Bischoff FZ; Heymach JV; Jaffe RB; Coleman RL; Sood AK
    Cancer Res; 2007 Jan; 67(1):281-8. PubMed ID: 17210709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A mathematical model to study low-dose metronomic scheduling for chemotherapy.
    Arora G; Bairagi N; Chatterjee S
    Math Biosci; 2024 Jun; 372():109186. PubMed ID: 38580078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
    Pietras K; Hanahan D
    J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metronomic chemotherapy: A relook at its basis and rationale.
    Rajasekaran T; Ng QS; Tan DS; Lim WT; Ang MK; Toh CK; Chowbay B; Kanesvaran R; Tan EH
    Cancer Lett; 2017 Mar; 388():328-333. PubMed ID: 28003122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose metronomic chemotherapy: from past experience to new paradigms in the treatment of cancer.
    Loven D; Hasnis E; Bertolini F; Shaked Y
    Drug Discov Today; 2013 Feb; 18(3-4):193-201. PubMed ID: 22868084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
    Kerbel RS
    Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metronomic Maintenance for High-Risk Pediatric Malignancies: One Size Will Not Fit All.
    André N; Orbach D; Pasquier E
    Trends Cancer; 2020 Oct; 6(10):819-828. PubMed ID: 32601045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A new treatment protocol targeting tumor vasculature--- metronomic chemotherapy combined radiotherapy].
    Qiu H; Wang GM
    Ai Zheng; 2007 Dec; 26(12):1392-6. PubMed ID: 18076810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.